Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tazarotene
- Development stage
- Approved
- Lead developer
- Allergan
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Administration
- Topical
01
Overview
Tazarotene is a third-generation topical retinoid used primarily for the treatment of plaque psoriasis and acne vulgaris. It is also indicated for reducing facial wrinkling and discoloration associated with photoaged skin. Tazarotene is a prodrug that undergoes rapid conversion in the skin to its active metabolite, tazarotenic acid. The active form binds to all three members of the retinoic acid receptor (RAR) family—RARα, RARβ, and RARγ—with relative selectivity for RARβ and RARγ. This binding modulates gene expression involved in cell proliferation and differentiation. The drug exerts antiproliferative effects on keratinocytes, normalizes their differentiation, and downregulates markers of inflammation[2][4][5][6]. Tazarotene was originally developed by Allergan.
- Brand names
- TazoracAvageFabiorArazlo
- Other names
- tazarotenic acid
02
Targets
RARA (Retinoic acid receptor alpha)RARG (Retinoic acid receptor gamma)RARB (Retinoic acid receptor beta)RXRA (Retinoid X receptor alpha)
Beyond the preview
Go deeper on tazarotene.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tazarotene.